| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 05/02/2002 | EP1200446A1 OXATHIEPINO 6,5- i b /i ]DIHYDROPYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 05/02/2002 | EP1200445A1 Thienopyranecarboxamide derivatives |
| 05/02/2002 | EP1200431A2 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands |
| 05/02/2002 | EP1200419A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 05/02/2002 | EP1200402A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 05/02/2002 | EP1200398A1 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors |
| 05/02/2002 | EP1200133A1 Manipulation of tissue or organ type using the notch pathway |
| 05/02/2002 | EP1200096A1 Tixocortol pivalate suspension, mouth-wash based thereon and packaging containing same |
| 05/02/2002 | EP1200094A1 Ophthalmic compositions containing antibiotics and nsaids |
| 05/02/2002 | EP1200085A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 05/02/2002 | EP1200079A2 2-aminotetralin derivatives for the therapy of glaucoma |
| 05/02/2002 | EP1200073A2 SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 05/02/2002 | EP1200066A1 Aqueous nasal formulation |
| 05/02/2002 | EP1173192A4 Methods and compositions for targeted drug delivery |
| 05/02/2002 | EP1146875A4 Myt1 kinase inhibitors |
| 05/02/2002 | EP0931086B1 Tetrahydronaphthalene derivatives and their therapeutic use |
| 05/02/2002 | EP0725643B1 Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents |
| 05/02/2002 | CA2428907A1 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy |
| 05/02/2002 | CA2427085A1 Transmembrane proteins |
| 05/02/2002 | CA2427005A1 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | CA2426736A1 Vegf peptides and their use for inhibiting angiogenesis |
| 05/02/2002 | CA2425283A1 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | CA2425280A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | CA2419373A1 Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery |
| 05/01/2002 | CN1347408A Use of maduraphthalazine derivs. as inhibitors of pro-inflammatory cytokins |
| 05/01/2002 | CN1347406A Carbamic acid derivs. and their use as metabotropic glutamate receptor ligands |
| 05/01/2002 | CN1347398A Salts of asiatic and madecassic acid suitable for preparation of pharmaceutical and cosmetic compositions |
| 05/01/2002 | CN1346828A Dicyclic aromatic compound and use thereof in human or animal medicine and cosmetic process |
| 05/01/2002 | CN1346668A Medicine for preventing and treating myopia and amlyopia |
| 05/01/2002 | CN1346649A Pterygium eliminating liquid |
| 05/01/2002 | CN1346648A Diemailing injection and its preparing process |
| 04/30/2002 | US6380261 Administering to retina antagonist of the nmda receptor-channel complex for therapy of proliferative vitreoretinopathy resulting from penetrating trauma, retinal tear, traction detachment, vitrectomy or intraocular surgery |
| 04/30/2002 | US6380258 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 04/30/2002 | US6380251 Therapy of ocular hypertension which comprises administering cyclopentane heptan(ene)oic acid or its 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives |
| 04/30/2002 | US6380250 Therapy of ocular hypertension which comprises administering cyclopentane heptan(ene)oic acid or its 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives |
| 04/30/2002 | US6380228 E.g., n-(2-phenylsulfonyl-1-ethyl)-3-(4-cyanophenyl)-2,3-dihydro-imidazo(2,1 -b)thiazole-5-carboxamide hydrochloride; treating cancer, neurofibromin benign proliferative disorder, retinal vascularization, and hepatitis delta |
| 04/30/2002 | US6380223 For therapy of diseases, such as obesity, diabetes, inflammation |
| 04/30/2002 | US6380200 Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications |
| 04/30/2002 | US6380198 Lowering the intraocular pressure |
| 04/30/2002 | US6379927 Retinoblastoma fusion proteins |
| 04/30/2002 | US6379692 Water insoluble drug ; adjustment of ph with acid |
| 04/30/2002 | US6378526 Methods of ophthalmic administration |
| 04/30/2002 | CA2042937C Treatment of ocular hypertension with a synergistic combination |
| 04/30/2002 | CA2042936C Treatment of ocular hypertension with a synergistic combination for ophthalmic use |
| 04/25/2002 | WO2002032961A2 Novel polypeptides and nucleic acids encoding same |
| 04/25/2002 | WO2002032901A2 Bridged piperazine derivatives |
| 04/25/2002 | WO2002032900A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 04/25/2002 | WO2002032883A1 Novel 4-benzyloxyphenyl derivative and use thereof |
| 04/25/2002 | WO2002032872A1 Nitrogenous aromatic ring compounds |
| 04/25/2002 | WO2002032864A1 Pharmaceutically active sulfanilide derivatives |
| 04/25/2002 | WO2002032862A2 Use of p38 inhibitors for the treatment of smoke inhalation |
| 04/25/2002 | WO2002032861A2 Orally active salts with tyrosine kinase activity |
| 04/25/2002 | WO2002032447A2 Cell damage inhibitor |
| 04/25/2002 | WO2002032422A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | WO2002032411A2 Combination of statins and sorbitol dehydrogenase inhibitors |
| 04/25/2002 | WO2002032406A2 Methods and products related to pulmonary delivery of polysaccharides |
| 04/25/2002 | WO2002032394A1 Delivery system and method of treating or preventing otitis media |
| 04/25/2002 | WO2002022112A9 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 04/25/2002 | WO2002010137A3 Indazole derivatives as JNK inhibitors |
| 04/25/2002 | WO2001083440A3 Synthesis and use of thienotriazolodiazepines |
| 04/25/2002 | WO2001072782A3 Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| 04/25/2002 | WO2001047533A3 INHIBITION OF GSK-3$g(b) |
| 04/25/2002 | WO2001042471A3 Polypeptides and polynucleotides encoding same |
| 04/25/2002 | WO2001002369A3 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 04/25/2002 | US20020049389 Noninvasive measurement of chemical substances |
| 04/25/2002 | US20020049326 Benzosulfones and related compositions and methods |
| 04/25/2002 | US20020049325 Calcium channel blockers |
| 04/25/2002 | US20020049281 Contacting with crosslinking agents so as to form two or more chemically distinct crosslinks between hyaluronic acid and the polymer; products with medical applications |
| 04/25/2002 | US20020049255 Method of treating neurodegenerative disorders of the retina and optic nerve head |
| 04/25/2002 | US20020049247 Administering lyposomes of photosensitive receptors or ligands targeted to specific tissues, exposure to light causing destruction of bound tissues; treatment of eye neovascular disease due to macular degeneration, diabetes... |
| 04/25/2002 | US20020049243 Pyrrolidine derivatives |
| 04/25/2002 | US20020049241 Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents |
| 04/25/2002 | US20020049239 Novel indole and benzothiazole derivatives |
| 04/25/2002 | US20020049238 Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 04/25/2002 | US20020049233 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 04/25/2002 | US20020049231 S(-)-3-aminothalidomide; treating wide variety of diseases including diabetic retinopathy |
| 04/25/2002 | US20020049226 Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis |
| 04/25/2002 | US20020049224 Alpha v integrin receptor antagonists |
| 04/25/2002 | US20020049222 Cyclopentyl modulators of chemokine receptor activity |
| 04/25/2002 | US20020049220 Substituted azoles |
| 04/25/2002 | US20020049215 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
| 04/25/2002 | US20020049212 Benzimidazole compounds and salts containing piperidine ring are useful in treatment or prevention or medical conditions selected from pain, and inflammatoy diseases; analgesics |
| 04/25/2002 | US20020049207 Nitrogen containing heterobicyclic compounds for treating disorders manifesting hypersecretion of corticotropin releasign factor(CRF) in a warm-blooded animals, such as stroke |
| 04/25/2002 | US20020049202 Administering halogenated amidino or oxyamidino compound to treat diseases caused by nitric oxide synthase |
| 04/25/2002 | US20020049195 Urea compounds that are muscarinic receptor antagonists and agonists, administering to the mammal the urea compound to treat urinary incontinence, chronic pulmonary obstructive disease, asthma, hyper salivation, blurred vision etc. |
| 04/25/2002 | US20020049183 Phospholipids, espeically phosphatidylethanolamines, covalently bound to physiologically acceptable monomers or polymers. |
| 04/25/2002 | US20020049182 Administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies. |
| 04/25/2002 | US20020049177 Detecting an aberrant level or bioactivity of or screening for a Wnt pathway component or a frizzled related protein gene product |
| 04/25/2002 | US20020048271 Methods and composition for restoring conformational stability of a protein of the p53 family |
| 04/25/2002 | DE10051321A1 New 2-(4-amino-piperidin-1-yl)-2-aryl-N-(phenylalkyl)-acetamides, are potent neurokinin antagonists, useful e.g. for treating allergic, inflammatory or central nervous system diseases |
| 04/25/2002 | DE10051320A1 New 2-(4-amino-piperidin-1-yl)-2-aryl-N-(phenylalkyl)-acetamides, are neurokinin antagonists having a long duration of action, useful e.g. for treating allergic, inflammatory or central nervous system diseases |
| 04/25/2002 | CA2426592A1 Combination of statins and sorbitol dehydrogenase inhibitors |
| 04/25/2002 | CA2426487A1 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | CA2426381A1 Cell damage inhibitor |
| 04/25/2002 | CA2424689A1 Orally active salts with tyrosine kinase activity |
| 04/25/2002 | CA2423933A1 Pharmaceutically active sulfanilide derivatives |
| 04/25/2002 | CA2423789A1 Bridged piperazine derivatives |
| 04/25/2002 | CA2423469A1 Methods and products related to pulmonary delivery of polysaccharides |
| 04/24/2002 | EP1199068A2 NMDA NR2B antagonists for treating depression and neurodegenerative disorders |
| 04/24/2002 | EP1199067A2 Prophylactic use of N-Methyl-D-Aspartate (NMDA) antagonists |